Orion Biotech Opportunities Corp. (ORIA) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
ONE VANDERBILT AVENUE, 26TH FLOOR NEW YORK, NY 10017 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 677 - Blank Checks (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 712,474 | |||
| Cash and cash equivalent | 712,474 | |||
| Prepaid expense | 640,559 | |||
| Total current assets: | 1,353,033 | |||
| Noncurrent Assets | ||||
| Intangible assets, net (including goodwill), including: | 5,000,001 | |||
| Other undisclosed intangible assets, net (including goodwill) | 5,000,001 | |||
| Other undisclosed noncurrent assets | 195,008,577 | |||
| Total noncurrent assets: | 200,008,578 | |||
| TOTAL ASSETS: | 201,361,611 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 81,631 | |||
| Accounts payable | 11,631 | |||
| Accrued liabilities | 70,000 | |||
| Total current liabilities: | 81,631 | |||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 15,035,251 | |||
| Deferred compensation liability, classified | 7,000,000 | |||
| Derivative instruments and hedges, liabilities | 8,035,251 | |||
| Total noncurrent liabilities: | 15,035,251 | |||
| Total liabilities: | 15,116,882 | |||
| Temporary equity, including noncontrolling interest | 200,000,000 | |||
| Equity | ||||
| Equity, attributable to parent, including: | (13,755,271) | |||
| Accumulated deficit | (13,755,771) | |||
| Other undisclosed equity, attributable to parent | 500 | |||
| Total equity: | (13,755,271) | |||
| TOTAL LIABILITIES AND EQUITY: | 201,361,611 | |||
Income Statement (P&L) (USD)
| 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|
| Operating expenses | (553,689) | ||
| Other undisclosed operating loss | (74,516) | ||
| Operating loss: | (628,205) | ||
| Nonoperating income (Investment Income, Nonoperating) | 17,156 | ||
| Interest and debt expense | (107,400) | ||
| Income (loss) from continuing operations: | (718,449) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (718,449) | |
| Other undisclosed net loss | (6,049) | ||
| Net income (loss): | (724,498) | ||
| Other undisclosed net income attributable to parent | |||
| Net income (loss) attributable to parent: | (724,498) | ||
| Preferred stock dividends and other adjustments | |||
| Net income (loss) available to common stockholders, diluted: | (724,498) | ||
Comprehensive Income (USD)
| 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|
| Net income (loss): | (724,498) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (724,498) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.